Targeting the embryonic gene Cripto-1 in cancer and beyond

Biogen-Idec has developed mouse monoclonal antibodies (mAbs) that bind to the NH2-terminal region, EGF-like domain or CFC motif of Cripto-1. The NH2 mAbs are binding antibodies, whereas the mAbs targeting the EGF-like or CFC domains are blocking antibodies. The binding B3.F6.1 antibody has been humanized and conjugated to the toxin DM4 for future use in cancer patients. The anti-CFC mAbs might potentially block interaction of Cripto-1 with GRP78. C3, C4 and C13 rat IgM monoclonal antibodies bind to the EGF-like domain of Cripto-1 and block tumor growth by induction of apoptosis and inhibition of Akt signaling pathway. The tetrametic tripeptide Cripto-1 Blocking peptide (CBP) blocks interaction of Cripto-1 with Alk4 and improves dopaminergic differentiation of ES cells in vitro and in vivo in a rat model of Parkinson’s disease.

Publication

Targeting the embryonic gene Cripto-1 in cancer and beyond. () Caterina Bianco, et al. Expert Opin Ther Pat. ;20(12):1739-1749. Figure: F1. All organisms Gallus gallus Homo sapiens Mus musculus Rattus norvegicus Capra hircus Drosophila melanogaster

Disease mentions